Xspray Pharma AB (publ) (”Xspray” or ”The Company”) has been approved for listing on Nasdaq Fist North. The first day of trading with Xspray’s shares will be on the 28th of September 2017.
As previously notified, Xspray Pharma AB (publ) has completed a new share issue before the planned listing on Nasdaq First North. The new share issue yielded, before issue expenses, approximately SEK 132 million and The Company has about 2,100 owners after the transaction. The audit of the company is now completed and Nasdaq has approved Xspray’s application for listing its shares for trading on First North.
”I am convinced that we can create significant value for our shareholders in the future, while at the same time bring improved cancer drugs to the market at a lower price. We look forward to delivering these values. You are welcome to join us in our exciting development” commented Per Andersson, CEO of Xspray Pharma AB.
First day of trading: 28th of September 2017
Redeye AB is The Company’s Certified Adviser.
For further information, please contact:
Per Andersson, CEO Xspray Pharma AB (publ)
Mobile: +46 (0)706 88 23 48
About Xspray Pharma
Xspray Pharma AB (publ) is a product development company with several product candidates under clinical development. Xspray uses its innovative and patented RightSize-technology in order to develop improved, as well as generic, versions of already marketed cancer drugs, mainly protein kinase inhibitors (PKI), in the treatment of cancer. The segment is the second largest within the oncology department and the drug prices are very high. Through the company’s innovative technology, Xspray can enter the market as a primary competitor to the current original drugs without interference from secondary patents. Xspray’s goal is to have three products ready for launch during the period 2020-2023, with a first product launch by 2021 at the latest. The Company has patents on production technology, equipment as well as on the resulting products. Xspray’s Certified Adviser is Redeye AB, www.redeye.se.
Xspray Pharma AB (publ)
Gunnar Asplunds Allé 32
171 69 Solna